Fertility company Spermosens has entered into an agreement with existing shareholders on a capital facility of SEK 4.85 million to support continued development and commercialization of the company's product. This is stated in a press release.The facility can be utilized during the period from June to December 2026 and is carried out through a directed issue of units, consisting of shares and warrants. The subscription price is set at a discount of 15 percent to the volume-weighted average price after exercise.Among the investors are CEO Tore Duvold and Chairman of the Board Ulrik Spork, as well as Mount Nebo Investments and seven other investors. The financing is conditional on approval at the annual general meeting on June 18.The capital is to be used primarily for clinical validation and commercial partnerships.